SCHEMBL6438879

SCHEMBL6438879

O=C(NN=Cc1ccccc1OS(=O)(=O)c1ccc(C(F)(F)F)cc1)c1ccc(Cl)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.57
NPC1 O15118 3/20 0.57
GAA P10253 2/20 0.57
HTT P42858 8/20 0.52
LMNA P02545 7/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
KMT2A Q03164 5/20 0.50
MEN1 O00255 2/20 0.50
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
EYA2 O00167 1/20 0.44
POLB P06746 2/20 0.44
PTBP1 P26599 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ENPP3 O14638 1/20 0.43
ENPP1 P22413 1/20 0.43
ENPP2 Q13822 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879920 1.00 RAB9A (0.57) RAB9ANPC1GAAHTTLMNA
SCHEMBL5879930 0.93 LMNA (0.51) RAB9ANPC1GAAHTTLMNA
SCHEMBL6375817 0.93 LMNA (0.51) RAB9ANPC1GAAHTTLMNA
SCHEMBL5880264 0.91 LMNA (0.54) RAB9ANPC1GAAHTTLMNA
SCHEMBL5880267 0.91 LMNA (0.54) RAB9ANPC1GAAHTTLMNA
SCHEMBL5880130 0.84 MAPT (0.50) RAB9ANPC1GAAHTTLMNA
SCHEMBL5879953 0.84 KMT2A (0.50) RAB9ANPC1GAAHTTLMNA
SCHEMBL5880133 0.84 MAPT (0.50) RAB9ANPC1GAAHTTLMNA
SCHEMBL5879956 0.84 KMT2A (0.50) RAB9ANPC1GAAHTTLMNA
SCHEMBL5879691 0.83 MAPT (0.52) GAAHTTLMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 RAB9A 3339/4885NPC1 365/4885GAA 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.